Pulmonology · Pulmonary Hypertension
The ongoing ADVANCE CAPACITY study could significantly impact the treatment landscape for pulmonary hypertension if ralinepag demonstrates improved exercise capacity. Positive trial results may lead to changes in treatment guidelines and increased market share for United Therapeutics.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/8/2026, 12:31:58 AM
Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The ongoing ADVANCE CAPACITY study could significantly impact the treatment landscape for pulmonary hypertension if ralinepag demonstrates improved exercise capacity. Positive trial results may lead to changes in treatment guidelines and increased market share for United Therapeutics. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 6 ranked evidence items (4 high-relevance).
Success in this trial may lead to expanded use of ralinepag, influencing market dynamics and treatment guidelines in pulmonary hypertension. The strongest clinical anchor is Endothelial Cell Dysfunction in Pulmonary Hypertension (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 3 regulatory and 0 competitive items passed relevance filtering for United Therapeutics.
The most relevant competitive pressure comes from Positive results could enhance ralinepag's position in the pulmonary hypertension market, competing with existing therapies..
Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). If the trial results are favorable, United Therapeutics may seek expanded indications for ralinepag, which could influence regulatory approvals and labeling.
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCoronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of COVID-19 Treatment Authorized for Emergency Use
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCondition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEndothelial Cell Dysfunction in Pulmonary Hypertension
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View sourcePrevalence of Pelvic Venous Congestion Syndrome in Female Patients With Lower Extremity Varicose Veins and Its Impact on Postoperative Quality of Life Improvement Following Radiofrequency Ablation: A
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceThe Effect of Bottle PEP Exercise on Expiratory Muscle Thickness, Strength, and Balance Parameters in Parkinson's Disease Patients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceProsthesis Versus Active Exercise Program in Patients With Rotator Cuff Arthropathy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePsilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceEfficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing ADVANCE CAPACITY study could significantly impact the treatment landscape for pulmonary hypertension if ralinepag demonstrates improved exercise capacity. Positive trial results may lead to changes in treatment guidelines and increased market share for United Therapeutics.
Successful trial outcomes could enhance ralinepag's competitive positioning against existing therapies, potentially increasing revenue and market share in the pulmonary hypertension sector.
If the trial results are favorable, United Therapeutics may seek expanded indications for ralinepag, which could influence regulatory approvals and labeling.
Monitor the trial results and any subsequent regulatory filings or updates from United Therapeutics.
Track for follow-up milestones; no immediate action required.